Cargando…

Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates

BACKGROUND & OBJECTIVES: In drug resistant, especially multi-drug resistant (MDR) tuberculosis, fluoroquinolones (FQs) are used as second line drugs. However, the incidence of FQ-resistant Mycobacterium tuberculosis is rapidly increasing which may be due to extensive use of FQs in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Mradula, Jadaun, G.P.S., Ramdas, Srivastava, K., Chauhan, Vipin, Mishra, Ritu, Gupta, Kavita, Nair, Surya, Chauhan, D.S., Sharma, V.D., Venkatesan, K., Katoch, V.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121286/
https://www.ncbi.nlm.nih.gov/pubmed/21623040
_version_ 1782206814643814400
author Singh, Mradula
Jadaun, G.P.S.
Ramdas,
Srivastava, K.
Chauhan, Vipin
Mishra, Ritu
Gupta, Kavita
Nair, Surya
Chauhan, D.S.
Sharma, V.D.
Venkatesan, K.
Katoch, V.M.
author_facet Singh, Mradula
Jadaun, G.P.S.
Ramdas,
Srivastava, K.
Chauhan, Vipin
Mishra, Ritu
Gupta, Kavita
Nair, Surya
Chauhan, D.S.
Sharma, V.D.
Venkatesan, K.
Katoch, V.M.
author_sort Singh, Mradula
collection PubMed
description BACKGROUND & OBJECTIVES: In drug resistant, especially multi-drug resistant (MDR) tuberculosis, fluoroquinolones (FQs) are used as second line drugs. However, the incidence of FQ-resistant Mycobacterium tuberculosis is rapidly increasing which may be due to extensive use of FQs in the treatment of various other diseases. The most important known mechanism i.e., gyrA mutation in FQ resistance is not observed in a significant proportion of FQ resistant M. tuberculosis isolates suggesting that the resistance may be because of other mechanisms such as an active drug efflux pump. In this study we evaluated the role of the efflux pumps in quinolone resistance by using various inhibitors such as carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP) and verapamil, in clinical isolates of M. tuberculosis. METHODS: A total of 55 M. tuberculosis clinical isolates [45 ofloxacin (OFL) resistant and 10 ofloxacin sensitive] were tested by Resazurin microtitre assay (REMA) to observe the changes in ofloxacin minimum inhibitory concentration (MIC) levels in presence of efflux inhibitors as compared to control (without efflux inhibitor). RESULTS: The MIC levels of OFL showed 2-8 folds reduction in presence of CCCP (16/45; 35.5%), verapamil (24/45; 53.3%) and DNP (21/45; 46.6%) while in case of isolates identified as OFL sensitive these did not show any effect on ofloxacin MICs. In 11 of 45 (24.5%) isolates change in MIC levels was observed with all the three inhibitors. Overall 30 (66.6%) isolates had reduction in OFL MIC after treatment with these inhibitors. A total of eight isolates were sequenced for gyrA gene, of which, seven (87.5%) showed known mutations. Of the eight sequenced isolates, seven (87.5%) showed 2 to 8 fold change in MIC in presence of efflux inhibitors. INTERPRETATION & CONCLUSIONS: Our findings suggest the involvement of active efflux pumps of both Major Facilitator Super Family (MFS) family (inhibited by CCCP and DNP) and ATP Binding Cassette (ABC) transporters (inhibited by verapamil) in the development of OFL resistance in M. tuberculosis isolates. Epidemiological significance of these findings needs to be determined in prospective studies with appropriate number of samples / isolates.
format Online
Article
Text
id pubmed-3121286
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31212862011-07-01 Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates Singh, Mradula Jadaun, G.P.S. Ramdas, Srivastava, K. Chauhan, Vipin Mishra, Ritu Gupta, Kavita Nair, Surya Chauhan, D.S. Sharma, V.D. Venkatesan, K. Katoch, V.M. Indian J Med Res Original Article BACKGROUND & OBJECTIVES: In drug resistant, especially multi-drug resistant (MDR) tuberculosis, fluoroquinolones (FQs) are used as second line drugs. However, the incidence of FQ-resistant Mycobacterium tuberculosis is rapidly increasing which may be due to extensive use of FQs in the treatment of various other diseases. The most important known mechanism i.e., gyrA mutation in FQ resistance is not observed in a significant proportion of FQ resistant M. tuberculosis isolates suggesting that the resistance may be because of other mechanisms such as an active drug efflux pump. In this study we evaluated the role of the efflux pumps in quinolone resistance by using various inhibitors such as carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP) and verapamil, in clinical isolates of M. tuberculosis. METHODS: A total of 55 M. tuberculosis clinical isolates [45 ofloxacin (OFL) resistant and 10 ofloxacin sensitive] were tested by Resazurin microtitre assay (REMA) to observe the changes in ofloxacin minimum inhibitory concentration (MIC) levels in presence of efflux inhibitors as compared to control (without efflux inhibitor). RESULTS: The MIC levels of OFL showed 2-8 folds reduction in presence of CCCP (16/45; 35.5%), verapamil (24/45; 53.3%) and DNP (21/45; 46.6%) while in case of isolates identified as OFL sensitive these did not show any effect on ofloxacin MICs. In 11 of 45 (24.5%) isolates change in MIC levels was observed with all the three inhibitors. Overall 30 (66.6%) isolates had reduction in OFL MIC after treatment with these inhibitors. A total of eight isolates were sequenced for gyrA gene, of which, seven (87.5%) showed known mutations. Of the eight sequenced isolates, seven (87.5%) showed 2 to 8 fold change in MIC in presence of efflux inhibitors. INTERPRETATION & CONCLUSIONS: Our findings suggest the involvement of active efflux pumps of both Major Facilitator Super Family (MFS) family (inhibited by CCCP and DNP) and ATP Binding Cassette (ABC) transporters (inhibited by verapamil) in the development of OFL resistance in M. tuberculosis isolates. Epidemiological significance of these findings needs to be determined in prospective studies with appropriate number of samples / isolates. Medknow Publications 2011-05 /pmc/articles/PMC3121286/ /pubmed/21623040 Text en © The Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Singh, Mradula
Jadaun, G.P.S.
Ramdas,
Srivastava, K.
Chauhan, Vipin
Mishra, Ritu
Gupta, Kavita
Nair, Surya
Chauhan, D.S.
Sharma, V.D.
Venkatesan, K.
Katoch, V.M.
Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title_full Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title_fullStr Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title_full_unstemmed Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title_short Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
title_sort effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant mycobacterium tuberculosis isolates
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121286/
https://www.ncbi.nlm.nih.gov/pubmed/21623040
work_keys_str_mv AT singhmradula effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT jadaungps effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT ramdas effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT srivastavak effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT chauhanvipin effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT mishraritu effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT guptakavita effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT nairsurya effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT chauhands effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT sharmavd effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT venkatesank effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates
AT katochvm effectofeffluxpumpinhibitorsondrugsusceptibilityofofloxacinresistantmycobacteriumtuberculosisisolates